Bausch + Lomb Corp.’s first-quarter results were unlike any other it will report in future quarters but a mirror image of the results its former parent firm reported for it earlier in the year.
Bausch + Lomb’s First Results Look Familiar
First Full-Year Guidance: $3.75bn To $3.8bn Revenues On 4% To 5% Gtowth
January-March results Bausch + Lomb reported on 8 June were included in Bausch Health’s results published in May on the same day it closed an IPO shares to separate its eye health and vision care business. Guidance it provided, however, was new and a first for Bausch + Lomb.
More from Earnings
• By
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
• By
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.